First tests on humans for an anti Covid nasal spray at the Irccs San Martino hospital in Genoa: the enrollment of patients will start from 15 May. The trial will verify the safety and efficacy of the spray (AOS2020), inhaled into the two nostrils 3/5 times a day, in reducing the viral load in the upper respiratory tract. This data, when available, will represent the starting point for the use of the product in the prevention of more serious symptoms and in reducing the contagiousness of people and the spread of the virus. The clinical study is conducted by the Hygiene Unit of the Genoese polyclinic and coordinated by Giancarlo Icardi, it will enroll a total of 57 patients infected with Covid-19, swab positive and with mild symptoms. The first results are expected within 4 months and, if positive, the product will be available within the year. The spray is an aqueous washing solution that contains 0.005% hypochlorous acid, an antimicrobial substance also produced by the cells of our immune system, made stable and pure and therefore inhalable thanks to Tehclo *, a nanotechnology conceived and developed by a team of Italians of the Italian-Swiss company Apr Applied Pharma Research sa, which has patented technological innovation. The results of the preliminary in vitro and in vivo tests, recently published in the Official Journal of the European Society of Otolaryngology, showed that the hypochlorous acid nasal spray eliminates Sars-Cov-2 in less than a minute without irritating the mucous membranes of nose and throat.The nasal spray, which will be produced in Italy, could also prove to be an additional protection in the future to prevent the spread of the infection, especially in high-risk environments such as public transport or schools.